Immunological Impact of Neoadjuvant Chemoradiotherapy in Patients with Borderline Resectable Pancreatic Ductal Adenocarcinoma
Immunological Impact of Neoadjuvant Chemoradiotherapy in Patients with Borderline Resectable Pancreatic Ductal Adenocarcinoma
复制标题
DOI：
10.1245/s10434-013-3390-y
复制
发表时间：
2014-02-01
影响因子：
3.7
通讯作者：
Endo, Itaru
中科院分区：
文献类型：
--
作者：
Homma, Yuki;Taniguchi, Koichi;Endo, Itaru
背景新辅助放化疗（NACRT）在胰腺导管腺癌肿瘤微环境中的免疫学效应知之甚少。本研究的目的是检查NACRT诱导的胰腺癌患者的免疫修饰。52例接受手术切除的胰腺癌患者入组本研究。22例患者接受了NACRT，而其他30例患者接受了手术切除而未接受NACRT。采用免疫组化方法检测肿瘤组织中CD4、CD8、CD68、CD163、Foxp3和主要组织相容性复合物I类（MHC I类）抗原的表达。接受NACRT的患者中CD4+和CD8+淋巴细胞的数量显著高于未接受NACRT的患者。各组间MHC I类分子表达无显著性差异。在NACRT组中，CD8+细胞高聚集的患者比CD8+细胞低聚集的患者的总生存期更长。NACRT可诱导肿瘤微环境中CD4+和CD8+细胞的积聚，并且CD8+细胞的高积聚可能是NACRT治疗的胰腺癌的良好预后标志。
Background. Little is known about the immunological effect of neoadjuvant chemoradiotherapy (NACRT) in the tumor microenvironment of pancreatic ductal adenocarcinoma. The objective of this study was to examine the immunological modifications induced by NACRT in patients with pancreatic cancer.Methods. Fifty-two patients with pancreatic cancer who underwent surgical resection were enrolled in this study. NACRT was administered to 22 patients, whereas the other 30 patients underwent surgical resection without NACRT. The resected tumor specimens were analyzed for the presence of tumor-infiltrating lymphocytes by using immunohistochemical staining for CD4, CD8, CD68, CD163, Foxp3, and major histocompatibility complex class I (MHC class I) antigen.Results. The number of CD4+ and CD8+ lymphocytes was significantly higher in patients who received NACRT than in those who did not receive NACRT. No significant difference in MHC class I expression was observed between the groups. In the NACRT group, patients with a high accumulation of CD8+ cells experienced longer overall survival than those with a low number of CD8+ cells.Conclusions. NACRT may induce the accumulation of CD4+ and CD8+ cells in the tumor microenvironment and a high accumulation of CD8+ cells might be a good prognostic marker for pancreatic cancer treated with NACRT.